The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Polypharmacology – Foe or Friend?
Open accessAbstract
Polypharmacology describes the activity of compounds at multiple targets. Current research focuses on two aspects of polypharmacology: (1) unintended polypharmacology can lead to adverse effects; (2) polypharmacology across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects. This perspective reviews these interconnected aspects of polypharmacology. The first part discusses the relevance of polypharmacology for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacological compounds early in the drug discovery process. The second part discusses the advantages of polypharmacology in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing. This perspective aims to provide a balanced view on polypharmacology, which can compromise the safety of drugs, but can also confer superior efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
REDFERN, W., CARLSSON, L., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., SIEGL, P., STRANG, I., SULLIVAN, A., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,532
Escape from Flatland 2: complexity and promiscuity
Lovering, F. (2013) · MedChemComm · doi:10.1039/c2md20347b · Cited by 1,444
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Hopkins, A. L. (2007) · Nature Biotechnology · doi:10.1038/nbt1007-1110 · Cited by 1,242
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Large-scale prediction and testing of drug activity on side-effect targets
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., et al. (2012) · Nature · doi:10.1038/nature11159 · Cited by 881
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
The influence of lipophilicity in drug discovery and design
Arnott, J. A., & Planey, S. L. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.714363 · Cited by 868
Automated design of ligands to polypharmacological profiles
Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X.-P., Norval, S., Sassano, M. F., Shin, A. I., Webster, L. A., et al. (2012) · Nature · doi:10.1038/nature11691 · Cited by 832
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
The efficiency of multi-target drugs: the network approach might help drug design
CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801
Multicomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
From magic bullets to designed multiple ligands
Morphy, R., Kay, C., & Rankovic, Z. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03163-0 · Cited by 729
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Molecular basis for sunitinib efficacy and future clinical development
Faivre, S., Demetri, G., Sargent, W., & Raymond, E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2380 · Cited by 721
Global organization of metabolic fluxes in the bacterium Escherichia coli
Almaas, E., Kovács, B., Vicsek, T., Oltvai, Z. N., & Barabási, A.-L. (2004) · Nature · doi:10.1038/nature02289 · Cited by 709
Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Target-based drug discovery: is something wrong?
Sams-Dodd, F. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03316-1 · Cited by 522
GLOWINSKI, J., & AXELROD, J. (1964) · Nature · doi:10.1038/2041318a0 · Cited by 512
Probing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
Polypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 479
Lopez-Munoz, F., & Alamo, C. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168001 · Cited by 476
Can we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
Sneader, W. (2005) · Wiley eBooks · doi:10.1002/0470015535 · Cited by 427
Whitebread, S., Hamon, J., Bojanic, D., & Urban, L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03632-9 · Cited by 404
Tzschentke, T. M., Christoph, T., Kögel, B., Schiene, K., Hennies, H.-H., Englberger, W., Haurand, M., Jahnel, U., Cremers, T. I. F. H., Friderichs, E., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.126052 · Cited by 395
Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Cobos, E., Entrena, J., Nieto, F., Cendan, C., & Pozo, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386113 · Cited by 376
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
Dar, A. C., Das, T. K., Shokat, K. M., & Cagan, R. L. (2012) · Nature · doi:10.1038/nature11127 · Cited by 333
Bender, A., Scheiber, J., Glick, M., Davies, J. W., Azzaoui, K., Hamon, J., Urban, L., Whitebread, S., & Jenkins, J. L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700026 · Cited by 327
Young, R. J., Green, D. V. S., Luscombe, C. N., & Hill, A. P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.001 · Cited by 311
Data completeness—the Achilles heel of drug-target networks
Mestres, J., Gregori-Puigjané, E., Valverde, S., & Solé, R. V. (2008) · Nature Biotechnology · doi:10.1038/nbt0908-983 · Cited by 265
Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges
Morphy, R., & Rankovic, Z. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315594 · Cited by 262
Serotonin receptors and heart valve disease—It was meant 2B
Hutcheson, J. D., Setola, V., Roth, B. L., & Merryman, W. D. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.008 · Cited by 252
Principles of Safety Pharmacology
Pugsley, M. K., Authier, S., & Curtis, M. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.280 · Cited by 250
Lipophilicity in PK design: methyl, ethyl, futile
van de Waterbeemd, H., Smith, D. A., & Jones, B. C. (2001) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008192010023 · Cited by 244
Multi-Target-Directed Ligands in Alzheimer's Disease Treatment
Bajda, M., Guzior, N., Ignasik, M., & Malawska, B. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797535245 · Cited by 240
Polypharmacology in a Single Drug: Multitarget Drugs
L. Bolognesi, M. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130004 · Cited by 230
Cavalli, A., & Bolognesi, M. L. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9004835 · Cited by 211
Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)
Mencher, S. K., & Wang, L. G. (2005) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-5-3 · Cited by 206
Mestres, J., Gregori-Puigjané, E., Valverde, S., & Solé, R. V. (2009) · Molecular BioSystems · doi:10.1039/b905821b · Cited by 203
Increased Exploratory Activity and Altered Response to LSD in Mice Lacking the 5-HT5A Receptor
Grailhe, R., Waeber, C., Dulawa, S. C., Hornung, J. P., Zhuang, X., Brunner, D., Geyer, M. A., & Hen, R. (1999) · Neuron · doi:10.1016/s0896-6273(00)80712-6 · Cited by 202
Selective Optimization of Side Activities: Another Way for Drug Discovery
Wermuth, C. G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030480f · Cited by 201
Millan, M. J. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.039 · Cited by 196
The value of drug repositioning in the current pharmaceutical market
Tobinick, E. L. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.2.1303818 · Cited by 193
In silico target fishing: Predicting biological targets from chemical structure
Jenkins, J. L., Bender, A., & Davies, J. W. (2006) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2006.12.008 · Cited by 189
Novel molecular targets for atrial fibrillation therapy
Dobrev, D., Carlsson, L., & Nattel, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3682 · Cited by 181
Martin, R. L., McDermott, J. S., Salmen, H. J., Palmatier, J., Cox, B. F., & Gintant, G. A. (2004) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200403000-00007 · Cited by 178
Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data
Azzaoui, K., Hamon, J., Faller, B., Whitebread, S., Jacoby, E., Bender, A., Jenkins, J. L., & Urban, L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700036 · Cited by 176
Hopkins, A. L. (2009) · Nature · doi:10.1038/462167a · Cited by 176
Molecular complexity and fragment-based drug discovery: ten years on
Leach, A. R., & Hann, M. M. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.008 · Cited by 169
How to design multi-target drugs: target search options in cellular networks
Korcsmáros, T., Szalay, M., Böde, C., Kovács, I. A., & Csermely, P. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.6.799 · Cited by 164
Peters, J., Schnider, P., Mattei, P., & Kansy, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800411 · Cited by 156
Self-citationPhysicochemical drug properties associated within vivotoxicological outcomes: a review
Price, D. A., Blagg, J., Jones, L. H., Greene, N., & Wager, T. T. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903042318 · Cited by 155
Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key
Haupt, V. J., Daminelli, S., & Schroeder, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065894 · Cited by 154
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent
Artis, D. R., Lin, J. J., Zhang, C., Wang, W., Mehra, U., Perreault, M., Erbe, D. V., Krupka, H. I., England, B. P., Arnold, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811325106 · Cited by 151
Huang, X., Setola, V., Yadav, P. N., Allen, J., Rogan, S. C., Hanson, B. J., Revankar, C. M., Robers, M., Doucette, C., & Roth, B. L. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058057 · Cited by 150
Compound promiscuity: what can we learn from current data?
Hu, Y., & Bajorath, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.03.002 · Cited by 146
Contributions of Molecular Properties to Drug Promiscuity
Tarcsay, Á., & Keserű, G. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301514n · Cited by 145
Selective optimization of side activities: the SOSA approach
Wermuth, C. G. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03686-x · Cited by 144
On the origins of drug polypharmacology
Jalencas, X., & Mestres, J. (2012) · MedChemComm · doi:10.1039/c2md20242e · Cited by 143
PubChem as a Source of Polypharmacology
Chen, B., Wild, D. J., & Guha, R. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci9001876 · Cited by 142
Wei, D., Jiang, X., Zhou, L., Chen, J., Chen, Z., He, C., Yang, K., Liu, Y., Pei, J., & Lai, L. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8010096 · Cited by 141
Predicting undesirable drug interactions with promiscuous proteins in silico
Ekins, S. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)03008-3 · Cited by 134
How many modes of action should an antibiotic have?
Brötz‐Oesterhelt, H., & Brunner, N. A. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.008 · Cited by 133
Novel paradigms for drug discovery: computational multitarget screening
Jenwitheesuk, E., HORST, J., Rivas, K. L., VanVoorhis, W. C., & Samudrala, R. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.11.007 · Cited by 132
Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development
Li, X., Frye, M. A., & Shelton, R. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.198 · Cited by 131
Sigma receptors: Potential targets for a new class of antidepressant drug
Fishback, J. A., Robson, M. J., Xu, Y., & Matsumoto, R. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.003 · Cited by 128
A Ligand-Based Approach to Mining the Chemogenomic Space of Drugs
Gregori‐Puigjané, E., & Mestres, J. (2008) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620708785739952 · Cited by 101
Hansen, J. M., & Harris, C. (2004) · Antioxidants and Redox Signaling · doi:10.1089/152308604771978291 · Cited by 98
(2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912 · Cited by 95
Emerging drugs for major depressive disorder
Connolly, K. R., & Thase, M. E. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.660146 · Cited by 95
Fosgerau, K., Jessen, L., Tolborg, J. L., Østerlund, T., Larsen, K. S., Rolsted, K., Brorson, M., Jelsing, J., & Neerup, T. S. R. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01676.x · Cited by 93
Kinase-likeness and Kinase-Privileged Fragments: Toward Virtual Polypharmacology
Aronov, A. M., McClain, B., Moody, C. S., & Murcko, M. A. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701021b · Cited by 91
Fliri, A. F. J., Loging, W., Thadeio, P. F., & Volkmann, R. A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050494g · Cited by 91
Can we discover pharmacological promiscuity early in the drug discovery process?
Peters, J., Hert, J., Bissantz, C., Hillebrecht, A., Gerebtzoff, G., Bendels, S., Tillier, F., Migeon, J., Fischer, H., Guba, W., et al. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.001 · Cited by 87
Self-citationPredictive value of animal studies in toxicology
Zbinden, G. (1991) · Regulatory Toxicology and Pharmacology · doi:10.1016/0273-2300(91)90004-f · Cited by 82
Quantitative Prediction of Antitarget Interaction Profiles for Chemical Compounds
Zakharov, A. V., Lagunin, A. A., Filimonov, D. A., & Poroikov, V. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300247r · Cited by 71
Theoretical Basis for the Activity of Thalidomide
Meierhofer, C., Dunzendorfer, S., & Wiedermann, C. J. (2001) · BioDrugs · doi:10.2165/00063030-200115100-00005 · Cited by 68
The Presynaptic Component of the Serotonergic System is Required for Clozapine's Efficacy
Yadav, P. N., Abbas, A. I., Farrell, M. S., Setola, V., Sciaky, N., Huang, X., Kroeze, W. K., Crawford, L. K., Piel, D., Keiser, M. J., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.195 · Cited by 65
Cardiovascular effects of antipsychotics
Michelsen, J., & Meyer, J. M. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.7.829 · Cited by 64
Multitarget ligands in antibacterial research: progress and opportunities
East, S. P., & Silver, L. L. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.743991 · Cited by 64
Structural Insights into the Molecular Basis of the Ligand Promiscuity
Sturm, N., Desaphy, J., Quinn, R. J., Rognan, D., & Kellenberger, E. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300196g · Cited by 63
Investigation of the Relationship between Topology and Selectivity for Druglike Molecules
Yang, Y., Chen, H., Nilsson, I., Mureşan, S., & Engkvist, O. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1008456 · Cited by 63
A series of case studies: practical methodology for identifying antinociceptive multi-target drugs
Pang, M.-H., Kim, Y., Jung, K. W., Cho, S., & Lee, D. H. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.003 · Cited by 62
Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists
Kvernmo, T., Houben, J. M., & Sylte, I. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608785161457 · Cited by 61
A chemogenomic approach to drug discovery: focus on cardiovascular diseases
Cases, M., & Mestres, J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.010 · Cited by 60
Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends
Issa, A. M., Phillips, K., Bebber, S. L. V., et al. (2007) · Current Drug Safety · doi:10.2174/157488607781668855 · Cited by 59
Ainsworth, C. (2011) · Nature Medicine · doi:10.1038/nm1011-1166 · Cited by 55
In Vitro Safety Pharmacology Profiling: What Else Beyond Herg?
Hamon, J., Whitebread, S., Techer-Etienne, V., Coq, H. L., Azzaoui, K., & Urbán, L. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.51 · Cited by 50
Towards Triple Vasopeptidase Inhibitors for the Treatment of Cardiovascular Diseases
Daull, P., Jeng, A. Y., & Battistini, B. J. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31813c6ca5 · Cited by 49
Molecular conformation and biological activity of central nervous system active drugs
Andrews, P. R., & Lloyd, E. J. (1982) · Medicinal Research Reviews · doi:10.1002/med.2610020404 · Cited by 47
"Promiscuous" Anticancer Drugs That Hit Multiple Targets May Thwart Resistance
Hampton, T. (2004) · JAMA · doi:10.1001/jama.292.4.419 · Cited by 46
The Future of Medicinal Chemistry
Hoffmann, T., & Metternich, R. E. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201677 · Cited by 46
Network Pharmacology for Cancer Drug Discovery: Are We There Yet?
Azmi, A. S. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.44 · Cited by 45
Antitargets: Prediction and Prevention of Drug Side Effects
(2008) · Methods and principles in medicinal chemistry · doi:10.1002/9783527621460 · Cited by 44
Hu, Y., & Bajorath, J. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9488-0 · Cited by 41
Murphy, S. M., Palmer, M., Poole, M. F., Padegimas, L., Hunady, K., Danzig, J., Gill, S. S., Gill, R. K., Ting, A. E., Sherf, B. A., et al. (2005) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2005.10.003 · Cited by 39
A critical assessment of modeling safety-related drug attrition
Muthas, D., Boyer, S. K., & Hasselgren, C. (2013) · MedChemComm · doi:10.1039/c3md00072a · Cited by 39
Cross-Pharmacology Analysis of G Protein-Coupled Receptors
Briansó, F., Carrascosa, M. C., Oprea, T. I., & Mestres, J. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611796391285 · Cited by 38
Volk, B., Nagy, B. J., Vas, S., Kostyalik, D., Simig, G., & Bagdy, G. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610791111588 · Cited by 36
How Promiscuous Are Pharmaceutically Relevant Compounds? A Data-Driven Assessment
Hu, Y., & Bajorath, J. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9421-y · Cited by 33
Drugs in development for the treatment of schizophrenia
Emsley, R. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903066756 · Cited by 33
Recent Advances in Studies on Hydroxamates as Matrix Metalloproteinase Inhibitors: A Review
Yadav, R. K., Gupta, S. P., Sharma, P. K., et al. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795471329 · Cited by 32
Carrieri, A., Pérez‐Nueno, V. I., Lentini, G., & Ritchie, D. W. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990028 · Cited by 32
The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet
Marchand, C. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.685653 · Cited by 29
Whitlock, G. A., Fish, P. V., Fray, M. J., Stobie, A., & Wakenhut, F. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.082 · Cited by 29
der Schyf, C. V., Mandel, S. A., Geldenhuys, W. J., Amit, T., Avramovich‐Tirosh, Y., Zheng, H., Fridkin, M., Gal, S., Weinreb, O., Am, O., et al. (2007) · Current Alzheimer Research · doi:10.2174/156720507783018226 · Cited by 28
Comparing Measures of Promiscuity and Exploring Their Relationship to Toxicity
Wang, X., & Greene, N. (2012) · Molecular Informatics · doi:10.1002/minf.201100148 · Cited by 27
Small kinase assay panels can provide a measure of selectivity
Brandt, P., Jensen, A. J., & Nilsson, J. W. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.083 · Cited by 24
Chemical probes for biological systems
García-Serna, R., & Mestres, J. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.11.004 · Cited by 24
Kaczorowski, G. J., García, M. L., Bode, J., Hess, S. D., & Patel, U. A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00078 · Cited by 24
Molecular basis for binding promiscuity of antagonist drugs
LaBella, F. S. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90385-i · Cited by 23
Network medicine in drug design: implications for neuroinflammation
Ghosh, S., & Basu, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.018 · Cited by 22
Computational Multitarget Drug Discovery
Horst, J. A., Laurenzi, A., Bernard, B. M., & Samudrala, R. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch13 · Cited by 18
Screening for Safety‐Relevant Off‐Target Activities
Urbán, L., Whitebread, S., Hamon, J., Mikhailov, D., & Azzaoui, K. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch2 · Cited by 17
Selective Optimization of Side Activities (SOSA): A Promising way for Drug Discovery
Langer, T., & Wermuth, C. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch11 · Cited by 16
Carbonic Anhydrases: Off Targets, Add‐On Activities, or Emerging Novel Targets?
Supuran, C. T. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch23 · Cited by 15
Polypharmacology as an Emerging Trend in Antibacterial Discovery
Silver, L. L. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch9 · Cited by 13
Polypharmacological Kinase Inhibitors: New Hopes for Cancer Therapy
Petrelli, A. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch8 · Cited by 13
Muthas, D., & Boyer, S. K. (2013) · Molecular Informatics · doi:10.1002/minf.201200088 · Cited by 13
‘Clean’ or ‘Dirty’ – Just How Selective do Drugs Need to Be?
Abbenante, G., Reid, R. C., & Fairlie, D. P. (2008) · Australian Journal of Chemistry · doi:10.1071/ch08186 · Cited by 12
Use of single-pill combination therapy in the evolving paradigm of hypertension management
Calhoun, D. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902980210 · Cited by 11
Pharmacological Promiscuity and Molecular Properties
Peters, J. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch3 · Cited by 10
Self-citationDeveloping selectively nonselective drugs for treating CNS disorders
Gray, J. A., & Roth, B. L. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.11.009 · Cited by 10
Combination Agents Versus Multi-Targeted Agents – Pros and Cons
Monzon, J. G., & Dancey, J. E. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912-00155 · Cited by 10
Predicting Drug Promiscuity Using Spherical Harmonic Surface Shape-Based Similarity Comparisons
Pérez‐Nueno, V. I. (2011) · The Open Conference Proceedings Journal · doi:10.2174/2210289201102010113 · Cited by 9
Multitargeted Drugs for Treatment of Alzheimer's Disease
Cavalli, A., & Bolognesi, M. L. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch22 · Cited by 7
Kinases as Antitargets in Genotoxicity
Kirchner, S. (2012) · doi:10.1002/9781118098141.ch4 · Cited by 6
Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil
Krishnamoorthy, S., & Lip, G. Y. H. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903114150 · Cited by 4
Prediction of Side Effects Based on Fingerprint Profiling and Data Mining
Migeon, J. (2012) · doi:10.1002/9781118098141.ch6 · Cited by 3
Borisy, A. A., Zimmermann, G. R., & Lehár, J. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch15 · Cited by 3
Activity at Cardiovascular Ion Channels: A Key Issue for Drug Discovery
Bell, I. M., Bilodeau, M. T., & Lagrutta, A. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch5 · Cited by 2
Therapeutic Potential of Small Molecules Modulating the Cyclooxygenase–5‐Lipoxygenase Pathway
Albrecht, W., & Laufer, S. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch19 · Cited by 2
Clinical Need and Rationale for Multi-Target Drugs in Psychiatry
Shahid, M. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912-00014 · Cited by 2
Riemer, C. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch17 · Cited by 2
A “Magic Shotgun” Perspective on Anticonvulsant Mechanisms
Bianchi, M. T., & Chuang, K. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch10 · Cited by 1
Cited by
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
Stereodivergence in Asymmetric Catalysis
Krautwald, S., & Carreira, E. M. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b13340 · Cited by 527
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Predictions of Ligand Selectivity from Absolute Binding Free Energy Calculations
Aldeghi, M., Heifetz, A., Bodkin, M. J., Knapp, S., & Biggin, P. C. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b11467 · Cited by 177
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
Metadata
- Authors
- Peters, J.-U.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-08-22
- Volume
- 56
- Issue
- 22
- Pages
- 8955-8971
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1999318478
- Cited by
- 465
- References
- 161
- FWCI
- 46.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
